How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,400 results for

Coronary Risk Stratification of Chest Pain

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Troponin for 30 day risk stratification in chest pain patients with ischaemic ECG.

ECG low risk chest pain, however a combination of the two points to a very high risk group. References Ohman EM. Armstrong PW. Christenson RH. Granger CB. Katus HA. Hamm CW. O'Hanesian MA. Wagner GS. Kleiman NS. Harrell FE Jr. Califf RM. Topol EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. New England Journal of Medicine. 335(18):1333-41, 1996 Oct 31 Wilcox G. Archer PD. Bailey M. Dziukas L. Lim CF. Schneider HG Measurement of cardiac (...) Troponin for 30 day risk stratification in chest pain patients with ischaemic ECG. BestBets: Troponin for 30 day risk stratification in chest pain patients with ischaemic ECG. Troponin for 30 day risk stratification in chest pain patients with ischaemic ECG. Report By: Stewart Teece - Clinical Research Fellow Search checked by Kerstin Hogg - Clinical Research Fellow Institution: EMERGE Date Submitted: 14th May 2003 Date Completed: 28th April 2009 Last Modified: 28th April 2009 Status: Green

2009 BestBETS

102. Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. Full Text available with Trip Pro

Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. Chest pain is a common complaint to emergency departments (EDs) and clinical risk factors are used to predict which patients are at risk for worse outcomes and mortality. The goal was to assess the novel biomarker midregional proadrenomedullin (MR-proADM) in prediction of mortality and major adverse cardiac events (MACE).This was a subanalysis (...) and had similar results in those with noncardiac diagnoses. MR-proADM concentrations were stratified by decile, and the cohort in the top decile had a 9.8% 6-month mortality risk versus 0.9% risk for those in the bottom nine deciles (p < 0.0001). MR-proADM, history of coronary artery disease (CAD), and hypertension were predictors of short-term MACE, while history of CAD, hypertension, cTnI, and MR-proADM were predictors of long-term MACE.In patients with chest pain, MR-proADM predicts mortality

2015 Academic Emergency Medicine

103. Inaccuracy of Thrombolysis in Myocardial Infarction and Global Registry in Acute Coronary Events scores in predicting outcome in ED patients with potential ischemic chest pain. (Abstract)

Inaccuracy of Thrombolysis in Myocardial Infarction and Global Registry in Acute Coronary Events scores in predicting outcome in ED patients with potential ischemic chest pain. The Thrombolysis in Myocardial Infarction (TIMI) and the Global Registry in Acute Coronary Events (GRACE) scores were largely evaluated and validated in stratifying risk of cardiovascular events in patients with chest pain and acute coronary syndrome. Our objective was to compare these 2 scores in predicting outcome (...) scores. At 1 year, the area under ROC was 0.67 (95% CI, 0.62-0.71) and 0.65 (95% CI, 0.60-0.70), respectively, for TIMI and GRACE scores.The TIMI and GRACE scores are not valid in short- and long-term risk stratification in our chest pain patients.Copyright © 2015 Elsevier Inc. All rights reserved.

2015 American Journal of Emergency Medicine

104. Diagnosis and Management of Acute Pulmonary Embolism Full Text available with Trip Pro

Integration of aggravating conditions and comorbidity into risk assessment of acute pulmonary embolism 20 5.6 Prognostic assessment strategy 20 6 Treatment in the acute phase 22 6.1 Haemodynamic and respiratory support 22 6.1.1 Oxygen therapy and ventilation 22 6.1.2 Pharmacological treatment of acute right ventricular failure 22 6.1.3 Mechanical circulatory support and oxygenation 23 6.1.4 Advanced life support in cardiac arrest 23 6.2 Initial anticoagulation 23 6.2.1 Parenteral anticoagulation 23 6.2.2 (...) normalized ratio IU International units i.v Intravenous IVC Inferior vena cava LA Left atrium LMWH Low-molecular weight heparin(s) LV Left ventricle/ventricular MRA Magnetic resonance angiography NCT National clinical trial NOAC(s) Non-vitamin K antagonist oral anticoagulant(s) NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association OBRI Outpatient Bleeding Risk Index o.d Omni die (once a day) OR Odds ratio PAH Pulmonary arterial hypertension PAP Pulmonary artery pressure PE

2019 European Society of Cardiology

105. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline

on the management of #COPD exacerbations from @ERStalk and @atscommunity Executive summary Chronic obstructive pulmonary disease (COPD) exacerbations are episodes of increased respiratory symptoms, particularly dyspnoea, cough and sputum. The European Respiratory Society (ERS) and American Thoracic Society (ATS) collaborated to develop guidelines that address questions regarding the treatment of COPD exacerbations that are not clearly answered by current guidelines. Key recommendations from the guidelines (...) Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Jadwiga A. Wedzicha (ERS co-chair) , Marc Miravitlles , John R. Hurst , Peter M.A

2017 European Respiratory Society

106. 15 hours of chest pain. Too late for thrombolytics, right? Unstable Angina still exists.

) ischemia. The troponin peaked at a low peak value of 2.0 ng/mL. What if the patient had presented 13 hours previously, after only 2 hours of chest burning? Imagine if she had come to the ED with chest pain of 1 hour duration. Her 0, 2, 4, and 6 hour troponins would have all been negative. Without a positive risk stratification score, she might have been sent home. Of course we do not know what the ECG would have shown, and it very likely would have shown at least subtle signs of LAD ischemia. If her (...) is a pathway just published for hs troponin T. Note that is still uses ECG and risk stratification!! Posted by Steve Smith at Labels: , , , , Reactions: 9 comments: Great point Stephen. I wouldn't have hesitated to send someone with that ECG to cath, regardless of time from onset. We have shown that high-sensitivity troponin does not elevate even in echo-proven myocardial ischemia on a stress test: Myocardial Ischemia on Cardiac Stress Testing Is Not Associated with Changes in Troponin T Levels

2017 Dr Smith's ECG Blog

107. Best Clinical Practice: Current Controversies in Evaluation of Low-Risk Chest Pain-Part 1. (Abstract)

risk, nor do they diagnose acute MI. CCTA is an anatomic evaluation of the coronary vasculature with literature support to decrease ED length of stay, though it is associated with downstream testing. Literature is controversial concerning further risk stratification in already low-risk patients.With nonischemic ECG and negative cardiac biomarker, the risk of ACS approaches < 1%. Use of stress test and CCTA for risk stratification of low-risk chest pain patients is controversial. These tests may (...) Best Clinical Practice: Current Controversies in Evaluation of Low-Risk Chest Pain-Part 1. Chest pain is a common presentation to the emergency department (ED), though the majority of patients are not diagnosed with acute coronary syndrome (ACS). Many patients are admitted to the hospital due to fear of ACS.Our aim was to investigate controversies in low-risk chest pain evaluation, including risk of missed ACS, stress test, and coronary computed tomography angiography (CCTA).Chest pain accounts

2016 Journal of Emergency Medicine

108. Non-invasive assessment of low- and intermediate-risk patients with chest pain Full Text available with Trip Pro

Non-invasive assessment of low- and intermediate-risk patients with chest pain Coronary artery disease (CAD) remains a significant global public health burden despite advancements in prevention and therapeutic strategies. Common non-invasive imaging modalities, anatomic and functional, are available for the assessment of patients with stable chest pain. Exercise electrocardiography is a long-standing method for evaluation for CAD and remains the initial test for the majority of patients who can (...) exercise adequately with a baseline interpretable electrocardiogram. The addition of cardiac imaging to exercise testing provides incremental benefit for accurate diagnosis for CAD and is particularly useful in patients who are unable to exercise adequately and/or have uninterpretable electrocardiograms. Radionuclide myocardial perfusion imaging and echocardiography with exercise or pharmacological stress provide high sensitivity and specificity in the detection and further risk stratification

2016 Trends in cardiovascular medicine

109. CCS Heart Failure Guidelines Update: Focus on FMR, SGLT2 Inhibitors, ARNI in HFpEF, and Amyloidosis Full Text available with Trip Pro

cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016; 68 : 1014-1020 after diagnosis. Different therapeutic modalities have been investigated in recent years using transthyretin stabilizers (eg, diflunisal and tafamidis), suppressors of ATTR synthesis (gene silencers), and amyloid fibrils degraders (doxycycline with tauroursodeoxycholic acid or ursodeoxycholic acid and epigallocatechin 3-gallate found in green tea extracts). Maurer M.S. Grogan D.R. Judge (...) on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recommendations and practical tips regarding the management of candidates for the following HF therapies: (1) transcatheter mitral valve repair in HF with reduced ejection fraction; (2) a novel treatment for transthyretin amyloidosis or transthyretin cardiac amyloidosis; (3

2020 Canadian Cardiovascular Society

110. Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Non-fatal Myocardial Infarction in Subjects without Chest Pain Syndrome from the CONFIRM Registry (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Mul Full Text available with Trip Pro

Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Non-fatal Myocardial Infarction in Subjects without Chest Pain Syndrome from the CONFIRM Registry (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Mul The predictive value of coronary computed tomographic angiography (cCTA) in subjects without chest pain syndrome (CPS) has not been established. We investigated the prognostic value of coronary artery disease detection by cCTA and determined (...) the incremental risk stratification benefit of cCTA findings compared with clinical risk factor scoring and coronary artery calcium scoring (CACS) for individuals without CPS.An open-label, 12-center, 6-country observational registry of 27 125 consecutive patients undergoing cCTA and CACS was queried, and 7590 individuals without CPS or history of coronary artery disease met the inclusion criteria. All-cause mortality and the composite of all-cause mortality and nonfatal myocardial infarction were measured

2012 Circulation

111. Sepsis as an important risk factor for gastrointestinal bleeding in acute coronary syndrome patients: Two case reports. Full Text available with Trip Pro

by authoritative guidelines for acute coronary syndrome (ACS), does not include sepsis as a bleeding risk factor.The 2 cases were about ACS with hemorrhagic complications. The first patient was an 88-year-old man with hypertension, gallstones, hepatic cysts, and chest pain; the second one was a 79-year-old man with chest pain and hypertension. These 2 ACS patients had no bleeding on admission; however, both patients suffered apparent gastrointestinal bleeding immediately after the development of sepsis (...) Sepsis as an important risk factor for gastrointestinal bleeding in acute coronary syndrome patients: Two case reports. Sepsis is a common stressor that may decrease microcirculation in the gastrointestinal tract in patients and increase the gastrointestinal bleeding risk of stress-related mucosal disease. However, the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) bleeding risk score, recommended

2018 Medicine

112. CT coronary angiography: new risks for low-risk chest pain. (Abstract)

-stratification strategies, demonstrate additional downstream costs and interventions, and result in multiple harms associated with radio-contrast and radiation exposure. Observing the widespread overdiagnosis of pulmonary embolism following availability of CT pulmonary angiogram as a practice pattern parallel, CTCA use for low-risk chest pain in the ED should be advanced only with caution. (...) CT coronary angiography: new risks for low-risk chest pain. Widespread conservative management of low-risk chest pain has motivated the development of a rapid triage strategy based on CT coronary angiography (CTCA) in the Emergency Department (ED). Recently, three prominent trials using this technology in the ED setting have presented results in support of its routine use. However, these studies fail to show the incremental prognostic value of CTCA over clinical and biomarker-based risk

2012 Emergency Medicine Journal

113. Genetic Testing for Hereditary Cardiac Disease

are similar to heart failure including shortness of breath, chest pain/tightness, fainting episodes and cardiac arrhythmias. The most serious complication of DCM is sudden, irregular heart rhythms that can be life threatening. Some individuals with DCM will have no symptoms throughout their lifetime. DCM is a heterogeneous condition caused by ischemia, systemic disease (e.g. mitochondrial or muscular dystrophy), toxins, or infection. Twenty to 50 percent of cases of idiopathic DCM are inherited. DCM can (...) be variable, ranging from no symptoms to shortness of breath or irregular heart rhythms, or sudden death. The irregular heart rhythms can occur without warning and may be life threatening. HCM has a prevalence of 1/500 individuals, making it one of the most common cardiac genetic diseases. It is inherited as an autosomal dominant trait with reduced penetrance. Family history focused on history of sudden death and age of onset in family members can be helpful in risk stratification. HCM is the most common

2020 AIM Specialty Health

114. Guidelines for Perioperative Care in Cardiac Surgery Enhanced Recovery After Surgery Society Recommendations

of body mass index and albumin on morbidity and mortality after cardiac surgery. J Thorac Cardiovasc Surg . 1999;118(5):866-873. doi: Kudsk KA, Tolley EA, DeWitt RC, et al. Preoperative albumin and surgical site identify surgical risk for major postoperative complications. JPEN J Parenter Enteral Nutr . 2003;27(1):1-9. doi: Lee EH, Kim WJ, Kim JY, et al. Effect of exogenous albumin on the incidence of postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass surgery (...) . 2018;105(1):321-328. doi: Day TG, Perring RR, Gofton K. Is manipulation of mediastinal chest drains useful or harmful after cardiac surgery? Interact Cardiovasc Thorac Surg . 2008;7(5):888-890. doi: Halm MA. To strip or not to strip? physiological effects of chest tube manipulation. Am J Crit Care . 2007;16(6):609-612. Boyacıoğlu K, Kalender M, Özkaynak B, Mert B, Kayalar N, Erentuğ V. A new use of Fogarty catheter: chest tube clearance. Heart Lung Circ . 2014;23(10):e229-e230. doi: Grieshaber P, Heim

2020 ERAS Society

115. AIM Clinical Appropriateness Guidelines for Genetic Testing for Hereditary Cardiac Disease

disease sufficient to cause global systolic dysfunction (Haas 2015). The symptoms of DCM are similar to heart failure including shortness of breath, chest pain/tightness, fainting episodes and cardiac arrhythmias. The most serious complication of DCM is sudden, irregular heart rhythms that can be life threatening. Some individuals with DCM will have no symptoms throughout their lifetime. DCM is a heterogeneous condition caused by ischemia, systemic disease (e.g. mitochondrial or muscular dystrophy (...) , Link MS, Marcus FI, McLeod CJ, Mestroni L, Priori SG, Saffitz JE, Sanatani S, Shimizu W, van Tintelen JP, Wilde AAM, Zareba W. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 May 9.pii:S1547-5271. PubMed PMID: 31078652. Selected References 1 Arbustini E, Weidemann F, Hall JL. Left ventricular noncompaction: a distinct cardiomyopathy or a trait shared by different cardiac diseases? J Am Coll Cardiol. 2014 Oct

2020 AIM Specialty Health

116. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

blood pressure in women with nonsevere HDP. , , , , Maternal risk stratification is needed to help guide patient care, including timing of delivery, and may help improve cardiovascular outcomes. One such model is the fullPIERS model (Preeclampsia Integrated Estimate of Risk), which was developed to identify predictors of adverse maternal outcomes in women who were admitted with preeclampsia or developed it after admission. Predictors included gestational age, symptoms of chest pain or dyspnea (...) , during pregnancy, and postpartum. BP indicates blood pressure. This scientific statement provides an overview of CVD during pregnancy, exclusive of congenital heart disease and sudden cardiac arrest, which are addressed in recent American Heart Association (AHA) scientific statements on these specific topics. , In addition, this scientific statement highlights the need for a cardio-obstetrics team for the management of CVD in women during a high-risk pregnancy. Physiological Changes During Pregnancy

2020 American Heart Association

117. Position Statement on the Evaluation of Patients Presenting with Suspected Acute Coronary Syndromes During the COVID-19 Pandemic

. The position statement complements, and should be read in conjunction with, the National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016: Section 2 ‘Assessment of Possible Cardiac Chest Pain’. [1] CSANZ Position Statement Acute Coronary Syndromes COVID19 21/04/20 3 Risk stratification High risk patients Criteria that identify patients ‘high risk’ of ACS or other important cardiac disease should (...) -24. 7. Chapman AR, Lee KK, McAllister DA, et al. Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. JAMA. 2017;318(19):1913-24. 8. Sandoval Y, Nowak R, deFilippi CR, et al. Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I. J Am Coll Cardiol. 2019;74(3):271-82. 9. Cullen L, Greenslade JH, Hawkins T, et al. Improved Assessment of Chest pain Trial (IMPACT

2020 Cardiac Society of Australia and New Zealand

118. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

al, 1996 38 Yes No Change in LVEF better Some patients received thymomodulin Ongoing trials Prednisone+AZA NCT01877746 234 Yes No Change in LVEF at 12 mo Virus negative required IVIG NCT00892112 50 Yes Yes Change in LVEF at 6 mo Evidence for parvovirus Anakinra NCT03018834 120 No Yes Days alive free of HF complications Diagnosis by chest pain, Tn, CMR AZA indicates azathioprine; CMR, cardiac magnetic resonance; CyA, cyclosporine A; HF, heart failure; HLA, human leukocyte antigen; IA, intra (...) and transfer of such patients to centers that have the capacity and experience to manage patients with FM is essential. Presenting Signs and Symptoms Clinical presentations vary widely, with or without systemic manifestations of an infection or inflammatory disorder. In the European Study of Epidemiology and Treatment of Inflammatory Heart Disease of 3055 patients, most of those screened had dyspnea followed by chest pain and arrhythmias such as atrial fibrillation, ventricular tachycardia, or heart block

2020 American Heart Association

119. Guidelines on Chronic Coronary Syndromes Full Text available with Trip Pro

Prospective Multicenter Imaging Study for Evaluation of Chest Pain PTP Pre-test probability RAS Renin−angiotensin system RCT Randomized clinical trial REACH Reduction of Atherothrombosis for Continued Health RIVER-PCI Ranolazine for Incomplete Vessel Revascularization Post‐Percutaneous Coronary Intervention SCORE Systematic COronary Risk Evaluation SCOT- HEART Scottish Computed Tomography of the HEART SIGNIFY Study Assessing the Morbidity–Mortality Benefits of the If Inhibitor Ivabradine in Patients (...) test 18 3.1.5.6 Invasive testing 19 3.1.6 Step 6: assess event risk 21 3.1.6.1 Definition of levels of risk 22 3.2 Lifestyle management 23 3.2.1 General management of patients with coronary artery disease 23 3.2.2 Lifestyle modification and control of risk factors 23 3.2.2.1 Smoking 23 3.2.2.2 Diet and alcohol 24 3.2.2.3 Weight management 24 3.2.2.4 Physical activity 24 3.2.2.5 Cardiac rehabilitation 24 3.2.2.6 Psychosocial factors 24 3.2.2.7 Environmental factors 25 3.2.2.8 Sexual activity 25

2019 European Society of Cardiology

120. Updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension Full Text available with Trip Pro

and echocardiography. If these investigations suggest the presence of PH/PHVD, chest X-ray and/or chest CT should be considered, followed by additional investigations. If PH/PHVD is severe, and the patient presents severely ill in overt heart failure and/or pulmonary vascular crisis, cardiac catheterization may be postponed and pharmacotherapy including intravenous prostanoids started immediately. CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension (...) , RP et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J . 2019 ; 53 , x 6 Lammers, AE, Apitz, C, Zartner, P et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart . 2016

2019 International Society for Heart and Lung Transplantation

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>